Fuchs, Michael; Jacob, Anne Sophie; Kaul, Helen; Kobe, Carsten; Kuhnert, Georg; Pabst, Thomas; Greil, Richard; Bröckelmann, Paul J; Topp, Max S; Just, Marianne; Hertenstein, Bernd; Soekler, Martin; Vogelhuber, Martin; Zijlstra, Josée M; Keller, Ulrich Bernd; Krause, Stefan W; Dührsen, Ulrich; Meissner, Julia; Viardot, Andreas; Eich, Hans-Theodor; ... (2024). Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma. Leukemia, 38(1), pp. 160-167. Springer Nature 10.1038/s41375-023-02064-y
|
Text
s41375-023-02064-y.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
The primary analysis of the GHSG HD16 trial indicated a significant loss of tumor control with PET-guided omission of radiotherapy (RT) in patients with early-stage favorable Hodgkin lymphoma (HL). This analysis reports long-term outcomes. Overall, 1150 patients aged 18-75 years with newly diagnosed early-stage favorable HL were randomized between standard combined-modality treatment (CMT) (2x ABVD followed by PET/CT [PET-2] and 20 Gy involved-field RT) and PET-2-guided treatment omitting RT in case of PET-2 negativity (Deauville score [DS] < 3). The study aimed at excluding inferiority of PET-2-guided treatment and assessing the prognostic impact of PET-2 in patients receiving CMT. At a median follow-up of 64 months, PET-2-negative patients had a 5-year progression-free survival (PFS) of 94.2% after CMT (n = 328) and 86.7% after ABVD alone (n = 300; HR = 2.05 [1.20-3.51]; p = 0.0072). 5-year OS was 98.3% and 98.8%, respectively (p = 0.14); 4/12 documented deaths were caused by second primary malignancies and only one by HL. Among patients assigned to CMT, 5-year PFS was better in PET-2-negative (n = 353; 94.0%) than in PET-2-positive patients (n = 340; 90.3%; p = 0.012). The difference was more pronounced when using DS4 as cut-off (DS 1-3: n = 571; 94.0% vs. DS ≥ 4: n = 122; 83.6%; p < 0.0001). Taken together, CMT should be considered standard treatment for early-stage favorable HL irrespective of the PET-2-result.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Pabst, Thomas Niklaus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1476-5551 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
17 Oct 2023 09:42 |
Last Modified: |
11 Jan 2024 00:14 |
Publisher DOI: |
10.1038/s41375-023-02064-y |
PubMed ID: |
37845285 |
BORIS DOI: |
10.48350/187244 |
URI: |
https://boris.unibe.ch/id/eprint/187244 |
Actions (login required)
 |
Edit item |